📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Integrated Summary of Efficacy (OBX-319)

Document ID: ISE-301
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH M4E(R2)

Integrated Summary of Efficacy — OBX-319

Product and integration context

OBX-319 is a humanized IgG1 bispecific monoclonal antibody that simultaneously engages the two B-lineage surface antigens CD19 and CD20 and is administered subcutaneously for the treatment of moderate-to-severe active Systemic Lupus Erythematosus (SLE). The molecule is produced by recombinant expression in a Chinese Hamster Ovary (CHO) cell line and purified by a platform downstream process (Protein A affinity capture followed by orthogonal polishing chromatography and dedicated viral-clearance steps); it is developed for licensure as a biological product under a Biologics License Application (21 CFR Part 601), with the underpinning quality, stability, characterisation, and nonclinical framework governed by ICH Q5A(R2), Q5C, Q6B, and S6(R1). By co-targeting CD20 (expressed from the pre-B stage through mature and memory B cells) and CD19 (expressed earlier in the lineage and persisting on plasmablasts and a subset of short-lived plasma cells), OBX-319 is designed to achieve deeper and broader depletion of the pathogenic B-cell compartment than single-antigen anti-CD20 agents, mediated through the intact human IgG1 Fc via antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). This dual-antigen depletion mechanism is the biological rationale for the disease-activity reductions summarised below in a disease driven by loss of tolerance to nuclear self-antigens, pathogenic autoantibody production (notably anti–double-stranded DNA [anti-dsDNA]), immune-complex deposition, and complement consumption.

Because OBX-319 does not cross-react with rodent CD19 or CD20, the pharmacologically relevant nonclinical species is the cynomolgus monkey; the definitive demonstration of pharmacology in the intended target — human B cells — is therefore provided by the clinical target-engagement and disease-activity data reported here. The integrated efficacy conclusion is a modality-appropriate synthesis of the confirmatory clinical endpoint, the dose-response gradient, and the mechanistically linked pharmacodynamic and serological biomarkers.

Scope of the integrated efficacy database

The confirmatory efficacy of OBX-319 is established by the pivotal Phase 3 study OBX319-301, a randomized, double-blind, placebo-controlled trial in which subjects with moderate-to-severe active SLE, all maintained on background standard of care (glucocorticoids, antimalarials, and/or conventional immunosuppressants), were randomized 1:1:1 to OBX-319 High-dose, OBX-319 Low-dose, or matched subcutaneous placebo and treated over a 52-week double-blind period. A total of 480 subjects were randomized (162 High-dose / 158 Low-dose / 160 placebo). Randomization was stratified to balance baseline disease activity (SLEDAI-2K category) and background standard-of-care therapy, and the double-blind design with matched subcutaneous placebo preserved masking across all arms for the full duration of the randomized period. The enrolled population had active disease at entry, with a mean baseline SLEDAI-2K of approximately 11, consistent with the target indication. Earlier-phase pharmacology, dose-ranging, and pharmacodynamic characterisation are supportive and directionally concordant, but the substantive efficacy contribution to this integrated summary derives from OBX319-301; the analyses below are presented as randomized to preserve the integrity of the treatment contrasts.

Efficacy endpoint definitions

The pre-specified primary efficacy endpoint was SRI-4 response at Week 52, operationalised as low disease activity (SLEDAI-2K <= 4). The two constituent instruments are standard, validated measures in SLE clinical development:

• SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000): a weighted composite of 24 descriptors across nine organ systems (theoretical range 0–105), in which higher scores denote greater global disease activity. A SLEDAI-2K <= 4 at Week 52 represents a state of low disease activity and was the operational definition of the responder endpoint.
• SRI-4 (SLE Responder Index-4): a composite requiring a ≥4-point reduction from baseline in SLEDAI-2K, no clinically meaningful worsening in organ-domain disease activity (no new BILAG A and no more than one new BILAG B domain), and no worsening of the Physician's Global Assessment, without discontinuation of randomized treatment or use of restricted/rescue medication beyond protocol thresholds.

The continuous form of the same disease-activity construct — LS-mean change from baseline in SLEDAI-2K at Week 52 — is reported alongside the binary responder endpoint to provide a complementary, dispersion-preserving view of the treatment effect.

Analysis populations

The primary analysis of continuous SLEDAI-2K change was performed on the Full Analysis Set (N = 480), comprising all randomized subjects analysed according to randomized treatment (OBX-319 High 162, OBX-319 Low 158, Placebo 160). The binary low-disease-activity (SLEDAI-2K <= 4) responder endpoint was evaluated on the pre-specified responder analysis set, with subjects who discontinued randomized treatment, used prohibited/rescue medication, or lacked an evaluable Week 52 assessment counted as non-responders; the corresponding per-arm denominators are shown in the responder table. Supportive per-protocol analyses were consistent with the Full Analysis Set and did not alter the interpretation.

Primary efficacy results

The integrated efficacy evidence for OBX-319 in Systemic Lupus Erythematosus (moderate-to-severe active) rests on OBX319-301. Primary endpoint SRI-4 response at Week 52 (operationalised as low disease activity, SLEDAI-2K <= 4):

Arm	N	LS-mean Δ SLEDAI-2K @ Wk 52 (points)	Diff vs placebo (95% CI)	p
OBX-319 High	162	-6.37	-2.91 (-3.12, -2.69)	0.0000
OBX-319 Low	158	-5.62	-2.17 (-2.38, -1.95)	0.0000
Placebo	160	-3.46	— (reference)	—

Responder analysis — Low disease activity (SLEDAI-2K <= 4)

Arm	N	Responders, n/N	Rate	Risk diff vs placebo (95% CI, %)	p
OBX-319 High	145	76/145	52.4%	46.4% (37.4, 55.4)	0.0000
OBX-319 Low	145	49/145	33.8%	27.8% (19.2, 36.4)	0.0000
Placebo	150	9/150	6.0%	— (reference)	—

Dose-response and clinical interpretation

Both OBX-319 regimens produced statistically significant and clinically meaningful improvements over placebo on both the continuous and responder formulations of the primary endpoint, with a consistent dose-ordered relationship (High-dose > Low-dose > placebo). On the continuous analysis, the LS-mean reduction in SLEDAI-2K at Week 52 was -6.37 points for High-dose and -5.62 points for Low-dose versus -3.46 for placebo, corresponding to placebo-adjusted treatment differences of -2.91 (95% CI -3.12, -2.69) and -2.17 (95% CI -2.38, -1.95), respectively. On the responder analysis, 52.4% (76/145) of High-dose and 33.8% (49/145) of Low-dose subjects achieved low disease activity (SLEDAI-2K <= 4) at Week 52, versus 6.0% (9/150) on placebo, yielding placebo-adjusted risk differences of 46.4 percentage points (95% CI 37.4, 55.4) for High-dose and 27.8 percentage points (95% CI 19.2, 36.4) for Low-dose. The magnitude of these differences is large relative to the modest placebo response typical of an active-disease SLE population maintained on background therapy, and the ordering of both the point estimates and the confidence-interval bounds across dose levels is internally consistent. The two confidence intervals for the responder risk difference exclude zero and do not overlap the placebo reference, supporting the selected High-dose regimen while confirming clinically relevant activity at the Low dose.

Pharmacodynamic and serological corroboration

The clinical efficacy findings are mechanistically corroborated by concordant pharmacodynamic and serological data that provide direct evidence of target engagement by this CD19 × CD20 bispecific antibody. On the active arms, OBX-319 produced near-complete depletion of circulating CD19+ B cells (from approximately 210 to approximately 7 cells/µL), whereas B-cell counts were essentially unchanged in the placebo arm. Depletion of the autoreactive B-cell compartment was accompanied by serological normalisation consistent with reduced pathogenic autoantibody production: anti-dsDNA titres fell and the complement components C3 and C4 normalised in association with clinical response. The temporal and directional coherence of profound peripheral B-cell depletion, declining anti-dsDNA, and recovering complement — each a recognised correlate of SLE disease activity — provides biologically plausible, target-engagement-linked support for the primary and continuous efficacy results and is consistent with the intended dual-antigen depletion mechanism. This convergence of clinical, pharmacodynamic, and immunological readouts is a central element of the integrated efficacy argument for a B-cell-depleting biologic.

Subgroup consistency, persistence, and durability of effect

Pre-specified secondary and supportive analyses of disease activity, organ-domain response (BILAG-based assessment), disease flare, and glucocorticoid dose reduction were directionally consistent with the primary result and reinforced the dose-ordered benefit, without introducing findings that would qualify the primary conclusion. Efficacy was consistent across the clinically relevant baseline subgroups examined (including baseline disease-activity category and background standard-of-care therapy), with treatment differences favouring both active regimens over placebo and no subgroup showing a qualitative reversal of effect. The primary endpoint was assessed at Week 52, and the observed reductions in disease activity were maintained through the end of the 52-week randomized period, consistent with sustained peripheral B-cell depletion over the treatment interval. The consistency of the treatment effect across the continuous and binary endpoints, across analysis populations (Full Analysis Set and per-protocol), and across the pharmacodynamic and serological biomarkers constitutes a coherent and mutually reinforcing efficacy package.

Immunogenicity and pharmacokinetic considerations

As an exogenous therapeutic protein, OBX-319 carries an inherent potential for immunogenicity; anti-drug antibodies (binding and neutralising) were monitored throughout using a tiered, validated assay strategy, and the presence of anti-drug antibodies did not attenuate the depletion pharmacodynamics or the disease-activity response in a manner that altered the efficacy conclusions. The pharmacokinetics of OBX-319 are governed by target-mediated drug disposition (TMDD): the near-complete and durable peripheral B-cell depletion observed on the active arms is consistent with target saturation over the subcutaneous dosing interval and supports the durability of the Week 52 effect. The relationship between exposure, immunogenicity status, B-cell depletion, and disease-activity response was examined and did not reveal a subgroup in which efficacy was materially eroded, consistent with the robustness of the dose-ordered treatment effect.

Substantial-evidence and integration considerations

The efficacy conclusion is anchored by a single adequate and well-controlled confirmatory trial (OBX319-301) whose result is internally replicated across two independently significant dose arms, both formulations of the primary endpoint (binary responder and continuous LS-mean), pre-specified sensitivity and per-protocol analyses, and a mechanistically confirmatory pharmacodynamic/serological data set. This weight and consistency of evidence — a large, precisely estimated, dose-ordered treatment effect corroborated by direct target-engagement biomarkers — supports a substantial-evidence conclusion of effectiveness for the intended indication. Consistent with the monoclonal-antibody modality, the endpoints and analyses focused on disease-activity response and mechanistically linked pharmacodynamic and serological biomarkers; assessments characteristic of small-molecule or unrelated pharmacological classes are not applicable to OBX-319 and were not part of the efficacy package. Safety, including the class-relevant risks of serious/opportunistic infection and hypogammaglobulinaemia associated with B-cell depletion, and injection-site/administration reactions and immunogenicity, is characterised separately in the Integrated Summary of Safety (ISS-301) and does not offset the demonstrated efficacy.

Effects were dose-ordered and consistent across the analysed populations, supporting a clinically meaningful benefit. ICH M4E(R2) §5.3.5.3.